NTLA LEAPS ITM CALL Strategy Update 1 : Riding the Momentum After Positive Trial Data and Technical Rebound

VIXTradingHub Analysis

📝 VIXTradingHub Analysis


NTLA LEAPS ITM CALL Strategy Update #1

🔍 Analyst Sentiment & Price Targets

📈 Recent Price Action & Technicals

  • NTLA is trading between $8.25–$9.11 today, high volatility zone. Volume is elevated at ~4–5 million shares, well above the ~2.8M average finance.yahoo.com+8marketbeat.com+8morningstar.com+8.

  • StockTradersDaily notes key levels: buy around $7.70 support, next resistance at $8.35 (with breakout target ~$8.98), and intraday resistance at $8.47, stop losses around 8.45–8.68 news.stocktradersdaily.com.

🧬 Fundamental & Trial News: NTLA LEAPS

🚨 Volume & Catalysts

  • AInvest analysis from early June flagged a ~5.7% spike that lacked technical triggers—driven instead by volume (~1.6M shares, 3× average), possibly due to sector rotation or whispers preceding the trial data ainvest.com.

🧾 Fundamentals at a Glance

Source: TradingView & MarketBeat timothysykes.com+3marketbeat.com+3news.stocktradersdaily.com+3

Metric Value
Market Cap ~$861M–$929M
YTD Price Change –26%
1‑Year Price Change –66%
Next Earnings Date July 31, 2025
Revenue (TTM) ~$45M
Net Income (TTM) –$481M to –$519M
Cash Ratio ~6.7×
Target Price Upside ~+300% to $35±
 

🧭 Summary & Outlook for NTLA LEAPS Strategy

  1. Strong Analyst Conviction: Sustained bullish sentiment with price targets averaging ~$33–35—pointing to substantial upside.

  2. Clinical Catalyst in Play: Positive Phase 1 data for NTLA‑2002 is fueling the narrative, alongside broader CRISPR/biotech revival.

  3. Technical Setup: Standout support at ~$7.70; key resistance at $8.35–8.47, with short-term breakout potential.

  4. Risk Profile: Still early-stage, loss-making, highly volatile (beta ~2.2). Cash buffers help, but speculative biotech nature remains.

✅ What Investors Should Watch

  • Breakouts above $8.47 on volume—could signal a swing trade with a target near $8.98.

  • Sustained performance post-data release—especially as NTLA-2002 progresses.

  • Upcoming earnings (July 31) for updated commercial/revenue guidance.

  • Downside protection—support near $7.70; a break below could test the next level.

🏁 Final Take: NTLA LEAPS

NTLA is a high-risk, high-reward biotech with core strengths in CRISPR gene editing. With bullish analyst views and phase 1 trial momentum, there’s potential for a significant rebound. But volatility remains high—consider clear entry/exit levels and size positions cautiously.

Here’s a NTLA LEAPS ITM Call Trading Strategy Update for Intellia Therapeutics (NTLA) using the:

🎯 NTLA Jan 15, 2027 $5 Call
📈 Delta: 0.86
💵 Premium: $6.00 per contract
📅 Days to Expiration: ~578 days
📊 Current Stock Price: $8.96 (as of June 16, 2025)

⚙️ Strategy Thesis: Deep ITM NTLA LEAPS Call (High Delta, High Conviction)

This trade is designed for long-term directional exposure to NTLA LEAPS with significantly less capital than buying shares, but with a stock-like movement due to the high delta (0.86).

📌 Entry Setup

Parameter Value
Stock Price $8.96
Strike Price $5.00
Intrinsic Value $3.96
Time Value Paid $2.04 ($6.00 – $3.96)
Breakeven Price $11.00 (Strike + Premium)
Delta (approximate) 0.86
Leverage Multiplier ~5x compared to buying stock
 

📈 Trade Objectives

Objective Target Price Option Value Est. ROI Est.
Modest Upside Target $12.00 ~$7.00–$7.50 +16%–25%
10% Stock Move (to $9.86)   ~$6.90 +15%
Bullish Breakout Target $15.00 ~$10.00–$11.50 +66%–91%
Long-term Target $20–$25 $15–$20 +150–230%
 
 

📉 Risk Management

Risk Scenario Description
Stock drops to $7.00 Option intrinsic ≈ $2.00, time value erodes
Support breach <$7 Review position; possible scale-in at $6.50–$7.00
Stock drops below $5 Entire option becomes OTM, potential full loss

You only risk $600 per contract, vs. $896 for 100 shares.

🔁 Scaling In / Scaling Out Plan: NTLA LEAPS

🔹 Scaling In (on weakness)

Condition Action
NTLA drops to $8.00 Add more contracts (Avg. cost <$6)
NTLA hits $7.00 Add 1–2 more (if conviction strong)
< $6.00 Reassess fundamentals & support
 
 

🔸 Scaling Out (on strength)

Trigger Price Action
$11.00 Sell 25% to reduce cost basis
$13.00 Sell 25% to lock in partial gains
$15.00+ Let remaining ride or roll to higher LEAPS
 
 

✅ Why This Setup Works for NTLA

  • ✅ High Delta (0.86) behaves like owning stock.

  • ✅ Limited downside to premium paid.

  • ✅ Large upside potential if NTLA recovers toward analyst targets ($30–$35).

  • ✅ Positive clinical news and insider/institutional interest recently.

  • ✅ Strong long-term catalyst (CRISPR + NTLA-2002 + pipeline).

🧠 Optional Enhancements: NTLA LEAPS

  • 🔁 Roll Strategy: If NTLA hits $15–$18 by mid-2026, roll to Jan 2029 $10 Calls for extended upside.

  • 🛡️ Hedge Strategy: Pair with short OTM Calls (e.g., Jan 2026 $17) for a diagonal if IV rises.

Learn more about LEAPS strategy from our Stock Options Education Series.

💰 5-Year Financial Overview for NTLA

Metric20242023202220212020
Revenue57,877,00036,275,00052,121,00033,053,00057,994,000
Cost of Revenue08,976,0007,572,0006,891,000150,408,000
Gross Profit47,592,00027,299,00044,549,00026,162,000-92,414,000
Operating Expense592,140,000551,566,000510,285,000300,903,000194,577,000
Operating Income-534,263,000-515,291,000-458,164,000-267,850,000-136,583,000
Net Income-519,021,000-481,192,000-490,208,000-259,718,000-125,568,000
EPS (Diluted)-5-5-6-4-2
EBITDA-523,978,000-506,315,000-450,592,000-260,959,000-130,272,000
EBIT-----
Tax Provision0016,022,000-8,174,000-8,663,000
Interest Income47,807,00049,832,0008,542,0001,283,0002,352,000
Interest Expense00000
Total Expenses-----
Basic Shares Outstanding98,849,00088,770,00076,972,00070,894,00055,987,000
Diluted Shares Outstanding98,849,00088,770,00076,972,00070,894,00055,987,000

🧠 Analysis & Opinions on NTLA

Loading widget...

📊 Technical Analysis Overview

Auto-loaded insights for today’s featured stock

Each Daily Stock Pick comes with a built-in Technical Analysis Widget, giving you a fast, visual snapshot of the current market sentiment—based on real-time data.

🔎 What You’ll See:

  • Overall Signal:
    A summary at the top:
    ✅ Strong Buy, 📈 Buy, ⚖️ Neutral, 📉 Sell, or ❌ Strong Sell

  • Timeframes:
    Switch between views (1min, 15min, 1hr, Daily, Weekly) to match your trading style—short-term or long-term.

  • Breakdown of Indicators:

    • Moving Averages – trend-following tools

    • Oscillators – momentum indicators like RSI & MACD

    • Pivots – support and resistance levels

💡 How to Use It:

This widget helps confirm or challenge your trading bias. Use it together with:

  • Our price targets

  • Options flow & volatility analysis

  • Institutional and insider sentiment

📝 VIXTradingHub Analysis


NTLA LEAPS ITM CALL Strategy Update #1

🔍 Analyst Sentiment & Price Targets

📈 Recent Price Action & Technicals

  • NTLA is trading between $8.25–$9.11 today, high volatility zone. Volume is elevated at ~4–5 million shares, well above the ~2.8M average finance.yahoo.com+8marketbeat.com+8morningstar.com+8.

  • StockTradersDaily notes key levels: buy around $7.70 support, next resistance at $8.35 (with breakout target ~$8.98), and intraday resistance at $8.47, stop losses around 8.45–8.68 news.stocktradersdaily.com.

🧬 Fundamental & Trial News: NTLA LEAPS

🚨 Volume & Catalysts

  • AInvest analysis from early June flagged a ~5.7% spike that lacked technical triggers—driven instead by volume (~1.6M shares, 3× average), possibly due to sector rotation or whispers preceding the trial data ainvest.com.

🧾 Fundamentals at a Glance

Source: TradingView & MarketBeat timothysykes.com+3marketbeat.com+3news.stocktradersdaily.com+3

Metric Value
Market Cap ~$861M–$929M
YTD Price Change –26%
1‑Year Price Change –66%
Next Earnings Date July 31, 2025
Revenue (TTM) ~$45M
Net Income (TTM) –$481M to –$519M
Cash Ratio ~6.7×
Target Price Upside ~+300% to $35±
 

🧭 Summary & Outlook for NTLA LEAPS Strategy

  1. Strong Analyst Conviction: Sustained bullish sentiment with price targets averaging ~$33–35—pointing to substantial upside.

  2. Clinical Catalyst in Play: Positive Phase 1 data for NTLA‑2002 is fueling the narrative, alongside broader CRISPR/biotech revival.

  3. Technical Setup: Standout support at ~$7.70; key resistance at $8.35–8.47, with short-term breakout potential.

  4. Risk Profile: Still early-stage, loss-making, highly volatile (beta ~2.2). Cash buffers help, but speculative biotech nature remains.

✅ What Investors Should Watch

  • Breakouts above $8.47 on volume—could signal a swing trade with a target near $8.98.

  • Sustained performance post-data release—especially as NTLA-2002 progresses.

  • Upcoming earnings (July 31) for updated commercial/revenue guidance.

  • Downside protection—support near $7.70; a break below could test the next level.

🏁 Final Take: NTLA LEAPS

NTLA is a high-risk, high-reward biotech with core strengths in CRISPR gene editing. With bullish analyst views and phase 1 trial momentum, there’s potential for a significant rebound. But volatility remains high—consider clear entry/exit levels and size positions cautiously.

Here’s a NTLA LEAPS ITM Call Trading Strategy Update for Intellia Therapeutics (NTLA) using the:

🎯 NTLA Jan 15, 2027 $5 Call
📈 Delta: 0.86
💵 Premium: $6.00 per contract
📅 Days to Expiration: ~578 days
📊 Current Stock Price: $8.96 (as of June 16, 2025)

⚙️ Strategy Thesis: Deep ITM NTLA LEAPS Call (High Delta, High Conviction)

This trade is designed for long-term directional exposure to NTLA LEAPS with significantly less capital than buying shares, but with a stock-like movement due to the high delta (0.86).

📌 Entry Setup

Parameter Value
Stock Price $8.96
Strike Price $5.00
Intrinsic Value $3.96
Time Value Paid $2.04 ($6.00 – $3.96)
Breakeven Price $11.00 (Strike + Premium)
Delta (approximate) 0.86
Leverage Multiplier ~5x compared to buying stock
 

📈 Trade Objectives

Objective Target Price Option Value Est. ROI Est.
Modest Upside Target $12.00 ~$7.00–$7.50 +16%–25%
10% Stock Move (to $9.86)   ~$6.90 +15%
Bullish Breakout Target $15.00 ~$10.00–$11.50 +66%–91%
Long-term Target $20–$25 $15–$20 +150–230%
 
 

📉 Risk Management

Risk Scenario Description
Stock drops to $7.00 Option intrinsic ≈ $2.00, time value erodes
Support breach <$7 Review position; possible scale-in at $6.50–$7.00
Stock drops below $5 Entire option becomes OTM, potential full loss

You only risk $600 per contract, vs. $896 for 100 shares.

🔁 Scaling In / Scaling Out Plan: NTLA LEAPS

🔹 Scaling In (on weakness)

Condition Action
NTLA drops to $8.00 Add more contracts (Avg. cost <$6)
NTLA hits $7.00 Add 1–2 more (if conviction strong)
< $6.00 Reassess fundamentals & support
 
 

🔸 Scaling Out (on strength)

Trigger Price Action
$11.00 Sell 25% to reduce cost basis
$13.00 Sell 25% to lock in partial gains
$15.00+ Let remaining ride or roll to higher LEAPS
 
 

✅ Why This Setup Works for NTLA

  • ✅ High Delta (0.86) behaves like owning stock.

  • ✅ Limited downside to premium paid.

  • ✅ Large upside potential if NTLA recovers toward analyst targets ($30–$35).

  • ✅ Positive clinical news and insider/institutional interest recently.

  • ✅ Strong long-term catalyst (CRISPR + NTLA-2002 + pipeline).

🧠 Optional Enhancements: NTLA LEAPS

  • 🔁 Roll Strategy: If NTLA hits $15–$18 by mid-2026, roll to Jan 2029 $10 Calls for extended upside.

  • 🛡️ Hedge Strategy: Pair with short OTM Calls (e.g., Jan 2026 $17) for a diagonal if IV rises.

Learn more about LEAPS strategy from our Stock Options Education Series.

💰 5-Year Financial Overview for NTLA

Metric20242023202220212020
Revenue57,877,00036,275,00052,121,00033,053,00057,994,000
Cost of Revenue08,976,0007,572,0006,891,000150,408,000
Gross Profit47,592,00027,299,00044,549,00026,162,000-92,414,000
Operating Expense592,140,000551,566,000510,285,000300,903,000194,577,000
Operating Income-534,263,000-515,291,000-458,164,000-267,850,000-136,583,000
Net Income-519,021,000-481,192,000-490,208,000-259,718,000-125,568,000
EPS (Diluted)-5-5-6-4-2
EBITDA-523,978,000-506,315,000-450,592,000-260,959,000-130,272,000
EBIT-----
Tax Provision0016,022,000-8,174,000-8,663,000
Interest Income47,807,00049,832,0008,542,0001,283,0002,352,000
Interest Expense00000
Total Expenses-----
Basic Shares Outstanding98,849,00088,770,00076,972,00070,894,00055,987,000
Diluted Shares Outstanding98,849,00088,770,00076,972,00070,894,00055,987,000

🧠 Analysis & Opinions on NTLA

💰 5-Year Financial Overview for NTLA

Metric20242023202220212020
Revenue57,877,00036,275,00052,121,00033,053,00057,994,000
Cost of Revenue08,976,0007,572,0006,891,000150,408,000
Gross Profit47,592,00027,299,00044,549,00026,162,000-92,414,000
Operating Expense592,140,000551,566,000510,285,000300,903,000194,577,000
Operating Income-534,263,000-515,291,000-458,164,000-267,850,000-136,583,000
Net Income-519,021,000-481,192,000-490,208,000-259,718,000-125,568,000
EPS (Diluted)-5-5-6-4-2
EBITDA-523,978,000-506,315,000-450,592,000-260,959,000-130,272,000
EBIT-----
Tax Provision0016,022,000-8,174,000-8,663,000
Interest Income47,807,00049,832,0008,542,0001,283,0002,352,000
Interest Expense00000
Total Expenses-----
Basic Shares Outstanding98,849,00088,770,00076,972,00070,894,00055,987,000
Diluted Shares Outstanding98,849,00088,770,00076,972,00070,894,00055,987,000

🧠 Analysis & Opinions on NTLA

📊 Technical Analysis Overview

Auto-loaded insights for today’s featured stock

Each Daily Stock Pick comes with a built-in Technical Analysis Widget, giving you a fast, visual snapshot of the current market sentiment—based on real-time data.

🔎 What You’ll See:

  • Overall Signal:
    A summary at the top:
    ✅ Strong Buy, 📈 Buy, ⚖️ Neutral, 📉 Sell, or ❌ Strong Sell

  • Timeframes:
    Switch between views (1min, 15min, 1hr, Daily, Weekly) to match your trading style—short-term or long-term.

  • Breakdown of Indicators:

    • Moving Averages – trend-following tools

    • Oscillators – momentum indicators like RSI & MACD

    • Pivots – support and resistance levels

💡 How to Use It:

This widget helps confirm or challenge your trading bias. Use it together with:

  • Our price targets

  • Options flow & volatility analysis

  • Institutional and insider sentiment

Options Chain

Select an expiration date to expand for table with strikes, greeks, and mark.

Join the Early Access List

“Get exclusive updates and launch bonuses.”

Scroll to Top